You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》疫苗公司瑞科生物遞上市申請 傳籌3億美元
阿思達克 07-19 14:54
疫苗公司江蘇瑞科生物提交上市申請,聯席保薦人為摩根士丹利、招銀國際及中信証券。早前有消息指,瑞科生物目標年內上市,集資約3億美元。

初步招股資料顯示,該公司目前擁有11款創新型疫苗,當中包括核心產品重組HPV九價疫苗REC603,目前處於III期臨床試驗階段;新冠肺炎疫苗(ReCOV)目前正在新西蘭進行I期臨床試驗。公司表示,目前正在為ReCOV建設符合GMP標準的生產設施,預計將於2021年年底前完工,年產能3億劑;同時亦正在建造HPV疫苗生產設施,產能500萬劑HPV九價疫苗或3,000萬劑HPV二價疫苗。

目前瑞科生物並無獲批准作商業銷售的產品,亦無自疫苗銷售產生任何收益,於今年首季錄得虧損2.46億元人民幣,而去年首季虧損為4,383.9萬元人民幣。

公司上市前投資者包括清池資本、淡馬錫、君聯資本、LYFE Capital、東方富海、紅杉資本及招銀國際等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account